Skip to main content

Activities & Updates

The first HTA on COVID-19 diagnostic technology from India (FELUDA test using CRISPR technology innovation)

Posted on
22 May 2023
Views
713

The first HTA on COVID-19 diagnostic technology from India (FELUDA test using CRISPR technology innovation) was done to provide evidence on SARS-CoV-2 testing policy and highlight the role of HTA in innovations. The findings of this HTA was presented by Prof. Kanchan Mukherjee in his keynote talk at the 2021 HTAi Asia Policy Forum virtual meeting (hosted by Japan). published.

Publication on this HTA can be viewed at: https://www.sciencedirect.com/ science/article/pii/S2211883721000034

Members worldwide

  

        

      

      

 

 

 

  

 

Members worldwide

HTAsiaLink welcomes
health technology assessment (HTA) organizations to join our community.

We aim to raise awareness about the pivotal role of HTA in evidence-based decision-making in the Asia-Pacific region and beyond while providing a platform for organizations to connect with renowned scholars and experts, exchange ideas, and foster valuable collaborations.